The effort could lead to Metafora's flow cytometry-based assay becoming the standard of care for diagnosing the disease in France.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The test, which detects DNA methylation markers, is being developed as an alternative to invasive cystoscopy, the current standard of care.
The developers maintain that the new assay would address an unmet market need for a DMD screening test.
The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.